| T13564 |
AZ7550
|
1421373-99-0
|
97.07%
|
|
|
AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
|
| T7129 |
(E/Z)-Necrosulfonamide
|
432531-71-0
|
98%
|
|
|
(E/Z)-Necrosulfonamide is a novel inhibitor of MLKL.
|
| T41027 |
MLKL-IN-2
|
899759-16-1
|
98.61%
|
|
|
MLKL-IN-2 is an MLKL inhibitor with potential tumorigenic activity for the study of cellular necrosis-related diseases.
|
| T24160 |
IM-54
|
861891-50-1
|
99.05%
|
|
|
IM-54 is a cell-permeable, effective, and selective necrosis inhibitor.
|
| T11520 |
GW806742X
|
579515-63-2
|
99.07%
|
|
|
GW806742X is an inhibitor of Mixed Lineage Kinase Domain-Like protein (MLKL) which binds the MLKL pseudokinase domain (Kd: 9.3 μM) with anti-necroptosis activity...
|
| T6904 |
Necrosulfonamide
|
1360614-48-7
|
99.17%
|
|
|
(E)-Necrosulfonamide ((E)-Necrosulfonamide) is an inhibitor of necroptosis. Blocks mixed lineage kinase domain-like protein (MLKL), a critical substrate of recep...
|
| T6104 |
Cerdulatinib hydrochloride
|
1369761-01-2
|
99.23%
|
|
|
Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for ...
|
| T6057 |
URMC-099
|
1229582-33-5
|
99.32%
|
|
|
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
|
| T2048 |
LY-364947
|
396129-53-6
|
99.65%
|
|
|
LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I.
|
| T2696 |
PRT062607 hydrochloride
|
1370261-97-4
|
99.93%
|
|
|
PRT062607 hydrochloride (P505-15 Hydrochloride) is a selective inhibitor of Syk (IC50: 1 nM). It displays at least 80-fold selectivity for Syk over other kinases...
|
| T13564L2 |
AZ7550 trimesylate salt
|
2319837-99-3
|
99.24%
|
|
|
AZ7550 trimesylate salt (AZ7550 Mesylate) is the active metabolite of ositinib, AZ7550 trimesylate salt inhibits IGF1R activity and can be used in the study of n...
|
